Exo Therapeutics — 1 certified H-1B filings (FY2021)
- 1
- Filings · FY2021
- $80k
- Median base · FY2021
- Senior Research Associate, Biology
- Top role · 1 all-time
- MA
- Top state · 1 all-time
Exo Therapeutics filed 1 certified H-1B LCAs in FY2021, with a median base salary of $80k and the middle 50% of offers between $80k and $80k. Across all years it has 1 certified filings since FY2021, most often for Senior Research Associate, Biology in Massachusetts.
How much does Exo Therapeutics pay H-1B workers?
Certified base salary by fiscal year: each box is the p25–p75 range, the heavy line the median, the whiskers reach p10–p90. $80k median in FY2021. Base pay only — hover a year for its figures.
How has Exo Therapeutics's H-1B hiring changed by year?
1 certified filings on record (FY2021).
| Fiscal year | Filings | vs prior FY | Median base |
|---|---|---|---|
| FY2021 | 1 | — | $80k |
Which wage levels does Exo Therapeutics file?
DOL prevailing-wage levels I–IV approximate experience tiers (I = entry, IV = fully competent). 0% of Exo Therapeutics's filings sit at Level III–IV. A heavy I–II skew reads as entry-level or contractor-style hiring; a heavy IV skew as senior in-house roles — and higher levels earn more lottery entries.
Share of 1 filings with a wage level · all years
- Level II100.0%1
What jobs does Exo Therapeutics sponsor for H-1B?
The most-filed job titles across all years (DOL titles, employer pay-grade codes stripped), with base-salary percentiles.
| Job title | Filings | Median base |
|---|---|---|
| Senior Research Associate, Biology | 1 | $80k |
Where does Exo Therapeutics hire H-1B workers?
Worksite states on the certified filings, all years. Deeper pink = more filings; hover a state for its figures.
| State | Filings | Median base |
|---|---|---|
| MA | 1 | $80k |
What has Exo Therapeutics filed recently?
Every certified LCA on record for Exo Therapeutics: job title, worksite, prevailing-wage level and the offered base salary.
| FY | Job title | Base salary |
|---|---|---|
| 2021 | Senior Research Associate, Biology | $80,000 |
Common questions about Exo Therapeutics's H-1B filings
- How much does Exo Therapeutics pay H-1B workers?
- Exo Therapeutics's median certified H-1B base salary is $80k (FY2021), from 1 filings. See the full salary distribution and percentiles above.
- How many H-1B workers does Exo Therapeutics sponsor?
- Exo Therapeutics has 1 certified H-1B Labor Condition Applications on record (FY2021).
- What jobs does Exo Therapeutics sponsor for H-1B?
- Exo Therapeutics's most-sponsored H-1B roles include Senior Research Associate, Biology.
- Where does Exo Therapeutics hire H-1B workers?
- Exo Therapeutics's top H-1B worksite states are MA.
- Does a certified LCA mean an H-1B visa was approved?
- No. A Labor Condition Application (LCA) is the Department of Labor attestation an employer must have certified before filing an H-1B petition with USCIS. It records the job, worksite and offered wage, but not whether the petition was filed, selected in the lottery, or approved. Filing counts measure intent to sponsor, not headcount.
- What salary do these figures show?
- The base annual wage offered on the certified LCA, converted to a yearly amount. Bonus, equity, overtime and benefits are not included, so total compensation is typically higher. Figures are medians and percentiles over certified filings; wages above $5,000,000 a year are excluded as data-entry errors.
- What do prevailing-wage levels I–IV mean?
- The Department of Labor assigns each LCA an OES wage level from I (entry) to IV (fully competent) for the occupation and area. Under the FY2027 wage-weighted H-1B lottery rule, a higher level earns more selection entries, so an employer's level mix is a proxy for how senior its sponsored roles are.
Keep exploring
Calculate your H-1B lottery odds →orCheck out the insights →
Source: U.S. Department of Labor, Office of Foreign Labor Certification — certified LCA disclosure data through June 2026 (FY2021). An LCA is not an approved visa; pay figures are base salary and exclude bonus and equity. Methodology →